Thomas Fishbein

Dr. Thomas Fishbein is the executive director of MedStar Georgetown Transplant Institute (MGTI), where he also serves as director of the Liver Diseases and Transplant Program and professor in the Departments of Surgery and Pediatrics. Additionally, he serves as vice president of Medical Operations and executive pillar chief for MedStar Medical Group. Board certified in Surgery, his special interests include small bowel/intestinal transplantation, pediatric liver transplantation, hepatobiliary surgery, liver transplant, portal hypertension surgery and pancreatic surgery.

Dr. Fishbein is an internationally acclaimed leader in transplantation of the intestine, liver and hepatobiliary surgery. He is known as one of a handful of international experts on intestinal transplantation who has developed new immunosuppressive regimens, surgical techniques and other treatments to improve outcomes. He was the first to use Sirolimus as primary immunosuppression for intestinal transplants, and to develop a protocol for inhibition of TNF alpha for chronic allograft enteropathy. More recently, he established the importance of innate immunity and alterations of the allograft microbiome to the understanding of transplant rejection.

He oversees clinical research at MGTI and is the principal investigator of numerous clinical trials. Under his leadership, MedStar Georgetown Transplant Institute surgeons have performed more than 10,000 transplants, and the institute is one of the highest volume organ transplant programs in the country.

Career History

• Advanced fellowships in transplantation at Mount Sinai Medical Center in New York and University of Pittsburgh
• Director of Liver Diseases and Transplant Program, MedStar Georgetown Transplant Institute
• Vice President of Medical Operations and Executive Pillar Chief, MedStar Medical Group
• Executive Director, MedStar Georgetown Transplant Institute (current position)

What Dr. Fishbein could bring to Executive Director at MedStar Georgetown Transplant Institute: With over three decades of surgical expertise and a track record of pioneering innovations in transplant medicine, Dr. Fishbein brings exceptional clinical credibility and research leadership. His role in scaling MGTI to become one of the nation's top transplant centers demonstrates his capacity to drive institutional growth, establish cutting-edge clinical programs, and mentor the next generation of transplant surgeons. His expertise in solving complex immunological challenges positions the institute to continue advancing outcomes for critically ill patients requiring organ transplantation.